Brief: Myriad Genetics Adds Folate Receptor Alpha To Precise Oncology Solutions Portfolio
24/05/2023 22:20
May 24 (Reuters) - Myriad Genetics Inc MYGN.O :
* MYRIAD GENETICS ADDS FOLATE RECEPTOR ALPHA TO PRECISE
ONCOLOGY
SOLUTIONS PORTFOLIO TO EXPAND TREATMENT OPTIONS FOR WOMEN LIVING
WITH OVARIAN CANCER
Source text for Eikon: ID:nGNXbtdFb0
Further company coverage: MYGN.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Myriad Genetics
See all newsUS STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
US STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple